Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents

Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize the activity of dimeric compounds at the structural, biochemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Salem, Ahmed F., Gambini, Luca, Udompholkul, Parima, Baggio, Carlo, Pellecchia, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281375/
https://www.ncbi.nlm.nih.gov/pubmed/32397624
http://dx.doi.org/10.3390/ph13050090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281375/
https://www.ncbi.nlm.nih.gov/pubmed/32397624
http://dx.doi.org/10.3390/ph13050090

Ejemplares similares